These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9330777)

  • 1. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide.
    Hadad S; Bialer M
    Biopharm Drug Dispos; 1997 Oct; 18(7):557-66. PubMed ID: 9330777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine.
    Hadad S; Bialer M
    Pharm Res; 1995 Jun; 12(6):905-10. PubMed ID: 7667199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid.
    Bialer M; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Shirvan M
    Biopharm Drug Dispos; 1996 Oct; 17(7):565-75. PubMed ID: 8894115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity.
    abu Salach O; Hadad S; Haj-Yehia A; Sussan S; Bialer M
    Pharm Res; 1994 Oct; 11(10):1429-34. PubMed ID: 7855047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disposition of valproyl glycinamide and valproyl glycine in rats.
    Blotnik S; Bergman F; Bialer M
    Pharm Res; 1997 Jul; 14(7):873-8. PubMed ID: 9244143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives.
    Sussan S; Dagan A; Bialer M
    Epilepsy Res; 1999 Jan; 33(1):11-21. PubMed ID: 10022362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide.
    Spiegelstein O; Yagen B; Bialer M
    Epilepsia; 1999 May; 40(5):545-52. PubMed ID: 10386522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structural requirements for the design of antiepileptic-glycine derivatives.
    Sussan S; Dagan A; Blotnik S; Bialer M
    Epilepsy Res; 1999 Apr; 34(2-3):207-20. PubMed ID: 10210036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs.
    Bialer M
    J Control Release; 1999 Nov; 62(1-2):187-92. PubMed ID: 10518650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.
    Bialer M; Hadad S; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Yagen B
    Pharm Res; 1996 Feb; 13(2):284-9. PubMed ID: 8932450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives.
    Levi M; Yagen B; Bialer M
    Pharm Res; 1997 Feb; 14(2):213-7. PubMed ID: 9090712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?
    Isoherranen N; Yagen B; Bialer M
    Curr Opin Neurol; 2003 Apr; 16(2):203-11. PubMed ID: 12644750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of CHF3381 as a novel antiepileptic agent.
    Villetti G; Bregola G; Bassani F; Bergamaschi M; Rondelli I; Pietra C; Simonato M
    Neuropharmacology; 2001 Jun; 40(7):866-78. PubMed ID: 11378157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New generation of valproic acid.
    Trojnar MK; Wierzchowska-Cioch E; Krzyzanowski M; Jargiełło M; Czuczwar SJ
    Pol J Pharmacol; 2004; 56(3):283-8. PubMed ID: 15215557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid.
    Shekh-Ahmad T; Mawasi H; McDonough JH; Finnell RH; Wlodarczyk BJ; Yavin E; Bialer M
    Epilepsia; 2014 Dec; 55(12):1944-52. PubMed ID: 25442425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.
    Semba J; Curzon G; Patsalos PN
    Br J Pharmacol; 1993 Apr; 108(4):1117-24. PubMed ID: 8485621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
    Blotnik S; Bergman F; Bialer M
    Drug Metab Dispos; 1996 May; 24(5):560-4. PubMed ID: 8723737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid.
    Spiegelstein O; Kroetz DL; Levy RH; Yagen B; Hurst SI; Levi M; Haj-Yehia A; Bialer M
    Pharm Res; 2000 Feb; 17(2):216-21. PubMed ID: 10751038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative.
    Shimshoni JA; Yagen B; Wlodarczyk B; Finnell RH; Schurig V; Bialer M
    Epilepsia; 2010 Mar; 51(3):323-32. PubMed ID: 19674061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs.
    Isoherranen N; Yagen B; Soback S; Roeder M; Schurig V; Bialer M
    Epilepsia; 2001 Jul; 42(7):825-30. PubMed ID: 11488879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.